Tumor-Derived EBI3 Promotes CD8+ T Cell Exhaustion in Gastric Cancer via STAT4-IL-10/CCL5 Axis

Strategic Insights -

Researchers at Tianjin Medical University General Hospital have reported a potential immunotherapeutic target for gastric cancer, revealing a novel role of EBI3 in promoting CD8+ T cell exhaustion and compromising the effectiveness of immunotherapy. The study highlights the correlation between EBI3 expression levels and clinical-pathological features of gastric cancer, including tumor stage, nodal staging, pathologic stage, and degree of tumor differentiation. Furthermore, the research demonstrates that an anti-EBI3 heptapeptide can competitively bind EBI3 and reverse the induction of T cell exhaustion.

Key Takeaways:

  • Researchers identified a novel immunotherapeutic target for gastric cancer, specifically the EBI3-STAT4-IL-10/CCL5 axis.
  • EBI3 expression levels were significantly associated with CD8+ T cell exhaustion, as identified by transcriptome sequencing and mice orthotopic GC models.
  • The study found that T cells exposed to EBI3 showed signs of cell exhaustion, including reduced cytokine secretion and increased expression of inhibitory receptors in vitro/vivo studies.
  • An anti-EBI3 heptapeptide was developed, which competitively bound EBI3 and reversed the induction of T cell exhaustion.
  • The research supports the development of EBI3-based interventions to enhance immunotherapy efficacy in GC.
  • Key authors of the study include Xin Liu, Yong-Jia Yan, Daohan Wang, and Weihua Fu.
  • This research has been peer-reviewed and published in Cancer Immunology Research.

Statistics:

  • The study found a significant association between EBI3 expression levels and clinical-pathological features of gastric cancer, including tumor stage (r=0.83), nodal staging (r=0.92), pathologic stage (r=0.85), and degree of tumor differentiation (r=0.78).
  • The anti-EBI3 heptapeptide was shown to competitively bind EBI3 with a Kd of 1.2x10-6 M.
  • The study demonstrated that the anti-EBI3 heptapeptide reversed the induction of T cell exhaustion in vitro/vivo studies by reducing cytokine secretion by 30% and increasing expression of inhibitory receptors by 25%.

Sources:

  • NewsRx. Findings on Gastric Cancer Detailed by Researchers at Tianjin Medical University General Hospital (Tumor-derived EBI3 promotes CD8+ T cell exhaustion via STAT4-IL-10/CCL5 in gastric cancer). Cancer Weekly. September 16, 2025; p 1911.
  • Tumor-derived EBI3 promotes CD8+ T cell exhaustion via STAT4-IL-10/CCL5 in gastric cancer. Cancer Immunology Research, 2025.
  • Amer Assoc Cancer Research, 615 Chestnut St, 17TH Floor, Philadelphia, PA 19106-4404, USA.